Background: Postoperative nausea and vomiting (PONV) is one of the most common adverse outcomes after\nstrabismus surgery. The primary outcome of this prospective, randomized, double-blind study was to compare the\nincidences of nausea or vomiting, and patient satisfaction of ondansetron and ramosetron after strabismus surgery\nunder general anesthesia. The secondary outcome was to investigate whether the number of involved extraocular\nmuscles (EOMs) in strabismus surgery was related to PONV.\nMethods: One hundred and five patients (aged 18ââ?¬â??60 years) undergoing strabismus surgery were allocated randomly\nto one of the three groups: placebo, ondansetron, or ramosetron. Patients received 2 ml placebo, 4 mg ondansetron, or\n0.3 mg ramosetron at the end of surgery. Each of the three groups was subdivided into two subgroups according to the\nnumber of EOMs involved in the surgery: subgroup S, single-muscle correction; subgroup M, multiple-muscle correction.\nThe incidences of nausea or vomiting, and patient satisfaction at 2, 24 and 48 h after surgery were analyzed as primary\noutcome. With regard to subgroups S and M in the placebo, ondansetron and ramosetron groups, incidences of nausea\nor vomiting, and patient satisfaction at 2, 24 and 48 h after surgery were analyzed as seconadary outcome.\nResults: The incidence of nausea was significantly lower in the ramosetron group at 2 h (9.4 %) than in the placebo (45.\n2 %) and ondansetron (34.7 %) groups (P < 0.05). The incidence of nausea was also significantly lower in the ramosetron\ngroup at 24 h than in the other groups (P < 0.05). Patients in the ramosetron group were more satisfied at 2 h (8.11 Ã?± 0.\n98) and 24 h (8.50 Ã?± 0.67) after surgery than those in the other groups (P < 0.05). With regard to subgroups S and M in\nthe placebo, ondansetron and ramosetron groups, there were no significant differences in either the incidence of\nnausea or patient satisfaction.
Loading....